NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells

Cancer Letters

Volumn 367, Issue 1, 2015, Pages 58-68

  Yu, Zhiyun ^a   Xie, Guifang ^a   Zhou, Guangtong ^a   Cheng, Ye ^a   Zhang, Guangtao ^a   Yao, Guangming ^a   Chen, Yong ^a   Li, Yunqian ^a   Zhao, Gang ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Glioma; NVP BEZ235; PI3K AKT mTOR; Temozolomide

Indexed keywords

ADENYLATE KINASE; CASPASE 3; CYCLIN A; CYCLIN B1; DACTOLISIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; S6 KINASE; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; DACARBAZINE; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL MODEL; ANTIGLIOMA ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVITY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MEIOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GLIOMA; IC50; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; G1 PHASE CELL CYCLE CHECKPOINTS; GLIOMA; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MALE; MICE, SCID; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939253515     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.007     Document Type: Article

References (34)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med 2005, 352:987-996.
2. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-197.
4. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., Wang Q.J., et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem 2010, 285:40461-40471.
5. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther 2008, 7:1851-1863.
6. Liu T.J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.M., et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther 2009, 8:2204-2210.
7. Hirose Y., Katayama M., Mirzoeva O.K., Berger M.S., Pieper R.O. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005, 65:4861-4869.
8. Molina J.R., Hayashi Y., Stephens C., Georgescu M.M. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010, 12:453-463.
9. Eyler C.E., Foo W.C., LaFiura K.M., McLendon R.E., Hjelmeland A.B., Rich J.N. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008, 26:3027-3036.
10. Caporali S., Levati L., Starace G., Ragone G., Bonmassar E., Alvino E., et al. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol. Pharmacol 2008, 74:173-183.
11. De Salvo M., Maresca G., D'Agnano I., Marchese R., Stigliano A., Gagliassi R., et al. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int. J. Radiat. Biol 2011, 87:518-533.
12. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
13. Chen L., Han L., Shi Z., Zhang K., Liu Y., Zheng Y., et al. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol. Med. Rep 2012, 5:575-579.
14. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
15. Gil del Alcazar C.R., Hardebeck M.C., Mukherjee B., Tomimatsu N., Gao X., Yan J., et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin. Cancer Res 2014, 20:1235-1248.
16. Frum R., Ramamoorthy M., Mohanraj L., Deb S., Deb S.P. MDM2 controls the timely expression of cyclin A to regulate the cell cycle. Mol. Cancer Res 2009, 7:1253-1267.
17. Fung T.K., Ma H.T., Poon R.Y. Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor. Mol. Biol. Cell 2007, 18:1861-1873.
18. Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H. NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle 2011, 10:3284-3299.
19. Saha A., Halder S., Upadhyay S.K., Lu J., Kumar P., Murakami M., et al. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 2011, 7. e1001275.
20. Mollah M.L., Park D.K., Park H.J. Cordyceps militaris Grown on Germinated Soybean Induces G2/M Cell Cycle Arrest through Downregulation of Cyclin B1 and Cdc25c in Human Colon Cancer HT-29 Cells. Evid. Based Complement. Alternat. Med 2012, 2012. 249217.
21. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev 2006, 58:621-681.
22. Chen X., Chen L., Chen J., Hu W., Gao H., Xie B., et al. ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res 1538, 2013:151-158.
23. Wang W.J., Long L.M., Yang N., Zhang Q.Q., Ji W.J., Zhao J.H., et al. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol. Sin 2013, 34:681-690.
24. Cerniglia G.J., Karar J., Tyagi S., Christofidou-Solomidou M., Rengan R., Koumenis C., et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol. Pharmacol 2012, 82:1230-1240.
25. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res 2008, 14:2900-2908.
26. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat 2002, 5:234-248.
27. Bellacosa A., Kumar C.C., Di Cristofano A., Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res 2005, 94:29-86.
28. Gallia G.L., Tyler B.M., Hann C.L., Siu I.M., Giranda V.L., Vescovi A.L., et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther 2009, 8:386-393.
29. Nyfeler B., Chen Y., Li X., Pinzon-Ortiz M., Wang Z., Reddy A., et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS ONE 2012, 7. e48548.
30. Wen P.Y., Lee E.Q., Reardon D.A., Ligon K.L., Alfred Yung W.K. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncol 2012, 14:819-829.
31. Prasad G., Sottero T., Yang X., Mueller S., James C.D., Weiss W.A., et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncol 2011, 13:384-392.
32. Choi E.J., Cho B.J., Lee D.J., Hwang Y.H., Chun S.H., Kim H.H., et al. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer 2014, 14:17.
33. Bendell J.C., Kurkjian C., Infante J.R., Bauer T.M., Burris H.A., Greco F.A., et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest. New Drugs 2015, 33(2):463-471.
34. Sun Z., Li Q., Zhang S., Chen J., Huang L., Ren J., et al. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation. Onco Targets Ther 2015, 8:269-277.